Amir Tahmasebipour,
Senior Microfluidics Scientist
Mekonos is a CGT platform company building the future of cell therapies on a chip. The company's System on a Chip merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale, offering an integrated solution for advanced cell and gene therapy development from R&D through Manufacturing.
Mekonos' ex vivo delivery technology uses silicon nanoneedles to enable high efficiency cargo delivery into any cell type, including primary immune cells, iPSCs and HSCs. The company's nanoneedle-based delivery system -- one needle, one cell -- offers single-cell precision at scale and a level of consistency unachievable with conventional delivery technologies. The Mekonos platform enables unique cell engineering capabilities, including nuclear delivery, multiplexing and dose control for hyper-precise ex-vivo delivery.
The company is headquartered in San Francisco and is backed by leading investors in both healthcare and technology.
|
|
|
